Clinical Trial

Reducing Cardiac-surgery Associated Acute Kidney Injury Occurence by Administering Angiotensin II

Study acronym: PAN-AKI
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The study intervention focuses on exploring the use of angiotensin II as a primary vasopressor compared to norepinephrine in cardiac surgery patients to investigate whether angiotensin II can reduce the occurrence of moderate/severe acute kidney injury (AKI). Despite its potential, as suggested by trials involving surgical patients, there is currently no human data confirming its effectiveness in preventing moderate/severe AKI in this context. The intervention aims to address this gap by evaluating angiotensin II's impact compared to norepinephrine.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-23.
Status change: Not Yet Recruiting → Recruiting 2025-07-15
Trial Details
NCT Number NCT06615102
Lead Sponsor Universität Münster
Collaborators: German Research Foundation
Conditions Cardiac Surgery, Vasoplegia
Enrollment 1,022 participants
Start Date 2025-03-31
Primary Completion 2027-01 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2025-07-18